TipHub

14.82

-0.31 -2.05%

As of 29 Jul 2026 · delayed

BSE Listed

GSM · GSM 0 · LT-ASM · ASM 1
What does GSM · GSM 0 · LT-ASM · ASM 1 mean?
BSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-09

Norris Medicines Ltd. (524414)

Volume: 336Avg Vol 1W: 537Avg Vol 1M: 2,52852W Range:1219.63
Key Ratios
Checked 9h ago
Market Cap₹15 Cr
Current Price₹14.82
Previous Close₹15.13
High / Low (52w)₹19.63 / ₹12
Volume336
Avg Vol (1W)537
Avg Vol (1M)2,528
Stock P/E
Book Value₹-15.07
Dividend Yield0%
ROE185.24%
ROA-217.22%
Revenue (TTM)
Revenue Growth
Profit Margin-343.98%
Total Debt
Shares Outstanding1 Cr
Face Value
EPS (TTM)₹0
P/B
Debt / Equity0
50 DMA₹14.74
200 DMA₹14.79
Day change-2.05%
SurveillanceGSM · GSM 0 · LT-ASM · ASM 1
Price Chart
14.82 7.66% · 1Y
191210K
2025-07-30
2026-07-29

20-day avg volume: 2K shares

Pros
  • Healthy return on equity of 185.2%.
  • Company is almost debt-free.
Cons
  • Company is loss-making at the latest annual result.
  • Negative book value per share.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹1 Cr₹1 Cr₹1 Cr₹3 Cr₹1 Cr₹2 Cr₹3 Cr₹1 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹1 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹1 Cr₹0 Cr
EPS
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹14 Cr₹16 Cr₹8 Cr₹12 Cr₹9 Cr₹8 Cr₹6 Cr₹6 Cr
EBITDA₹-2 Cr₹-1 Cr₹-3 Cr₹-2 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-1 Cr
Net Profit₹-3 Cr₹-2 Cr₹-3 Cr₹-5 Cr₹-3 Cr₹-2 Cr₹-1 Cr₹-1 Cr
EPS-2.51-1.68-2.84-4.96-3.26-1.75-1.19-1.24
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹21 Cr₹20 Cr₹21 Cr₹20 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr
Total Liabilities₹19 Cr₹20 Cr₹23 Cr₹27 Cr₹25 Cr₹26 Cr₹28 Cr₹29 Cr
Equity₹2 Cr₹0 Cr₹-2 Cr₹-7 Cr₹-11 Cr₹-12 Cr₹-14 Cr₹-15 Cr
Total Debt
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹1 Cr₹-1 Cr₹1 Cr₹0 Cr₹1 Cr
Investing₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Financing₹-1 Cr₹1 Cr₹-1 Cr₹0 Cr₹-1 Cr
Free Cash Flow₹1 Cr₹-1 Cr₹1 Cr₹0 Cr₹1 Cr
Shareholding
Promoter 34.01% Institutions 0.07% Public 65.92%
Efficiency & Working Capital
ROCE3.4%
Interest Coverage-1.7
Dividend Payout
Debtor Days88 d
Inventory Days259 d
Payable Days161 d
Cash Conversion Cycle186 d
Working Capital Days347 d
Shareholding Details

As of 2026-06-30

Promoter34%
FII0%
DII0.1%
Institutions0.1%
Public65.9%
Promoter Pledge0%
No. of Shareholders25,777
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters34%34%34%34%34%34%34%34%34%34%34%34%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%
Public65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders25,24225,31725,51725,40025,49825,65925,81525,95025,89525,79125,77725,777
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Fab Metals Private LimitedPublic Shareholding42%41,99,259
Vimal D ShahShareholding of Promoter and Promoter Group23.6%23,60,441
Navsarjan Investment & Trading Pvt LtdShareholding of Promoter and Promoter Group10%10,00,000
Lkp Securities LimitedPublic Shareholding1.5%1,50,000
Dhirendra Kantilal Shah HufShareholding of Promoter and Promoter Group0.3%34,350
Navnit Jethabhai PatelShareholding of Promoter and Promoter Group0%3,840
Milind L UpadhyayaShareholding of Promoter and Promoter Group0%1,500
Nimish Bhishma ThakoreShareholding of Promoter and Promoter Group0%1,440
Board of Directors
NameDesignationYear
Vimal D ShahChairman / Executive Director / Managing Director2025
Angamuthu VadivelIndependent Non Exe. Director2025
Praveen BafnaNon-Exec & Non-Independent Dir2025
Sathya VenkatachalamIndependent Non Exe. Director2025
Priyanka LohiaCompany Sec. & Compli. Officer2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10101010
Company Information
Incorporated1990
ChairmanVimal D Shah
AuditorBahedia & Associates
🌐 www.norrispharma.com

📍 Plot No 801/P & 802, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search